Navigation Links
Delivering drugs to the brain: New research into targeted treatment of Alzheimer's
Date:12/7/2010

Troy, N.Y. Pankaj Karande, a Rensselaer Polytechnic Institute assistant professor of chemical and biological engineering, is among a new generation of scientists and engineers developing exciting and novel new techniques to treat some of the most complex brain illnesses, including Alzheimer's disease, Parkinson's disease, traumatic brain injury, and brain cancer. His research has already attracted the interest of the Goldhirsh Foundation and now has garnered the support of the Alzheimer's Association with an additional $80,000 in research funding.

Karande's research seeks to open the natural and protective barriers that exist in the brain to allow for the targeted delivery of drugs into the brain. Such drug delivery systems could limit the side effects experienced by patients using existing drugs to treat brain illness, increase the effectiveness of current drug treatments, lead to the development of new drugs, and even allow drugs that previously failed in clinical trials to be reconsidered utilizing new delivery methods.

"You can have the best and most promising of drugs, but if it doesn't go where it is needed, then it won't be effective," Karande said. "There are a lot of new discoveries within the area of drug development, even related to treatment of Alzheimer's. There is not a drug discovery problem; drug delivery is really the challenge."

The problem with delivering drugs to the brain is that the brain is exceptionally good at keeping out foreign substances. The main obstacle to entry is called the blood-brain barrier. Blood vessels within the brain are lined with "Velcro-like" cells that interlock so tightly that very little is allowed to pass through into the system.

But entry is not impossible, according to Karande. "There are more blood vessels in the brain than anywhere else in the body. The supply lines are there, we simply need to understand how to open them."

Karande's hypothesis is that the key to
'/>"/>

Contact: Gabrielle DeMarco
demarg@rpi.edu
518-956-0701
Rensselaer Polytechnic Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Molecules delivering drugs as they walk
2. Conserving nature and dollars: Delivering cost-effective biodiversity protection
3. Study shows that delivering stem cells improves repair of major bone injuries in rats
4. Delivering medicine directly into a tumor
5. Synthetic cells shed biological insights while delivering battery power
6. Preventing ear infections in the future: Delivering vaccine through the skin
7. HIV drugs interfere with blood sugar, lead to insulin resistance
8. Multiple sclerosis drug serves as model for potential drugs to treat botulism poisoning
9. Scientists learn more about how kidneys fail and how new drugs may intervene
10. Drugstore of the future -- new drugs from an old source
11. Video-game technology may speed development of new drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  Leading identity analyst firm Acuity Market Intelligence forecasts ... population will have a chip-based National eID card, including ... Asia , with its vast population, ... than 60% of all National eID cards issued between ... Global National eID Industry Report: 2014 Edition" ...
(Date:10/19/2014)... over the last 30 years contributed only marginally ... that time, according to a new study published ... "Energy access is fundamental to development: it brings ... communication, and health," says IIASA researcher Shonali Pachauri, ... access is widely agreed to be an important ...
(Date:10/18/2014)... a group of 2,000 patients referred for evaluation ... potential molecular diagnosis for 25 percent, including detection ... new mutations contributing to disease, according to a ... is being released to coincide with the American ... sequencing analyzes the exons or coding regions of ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... of its kind, researchers at Queens College and Mount ... status (SES) and maternal gestational diabetes together may cause ... (ADHD) in six year olds. The data are published ... Pediatrics and Adolescent Medicine , one of the JAMA/Archives ...
... Group, Inc. (Pinksheets: EVRM) would like to issue the ... foremost, I want to thank our supporters; it has ... Evermedia Group, advancing the interests of wholly owned subsidiaries: ... have been fortunate to work with many outstanding professionals ...
... Chimpanzees, orangutans, gorillas and bonobos make more sophisticated decisions ... success, based on what they know and the likelihood to ... Daniel Haun, published on December 21 in the online journal ... human decision-making as well. The authors of the ...
Cached Biology News:Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2The Evermedia Group 2011 Year in Review 2The Evermedia Group 2011 Year in Review 3The Evermedia Group 2011 Year in Review 4
(Date:10/22/2014)... WriteResult, LLC – a premier provider of ... a team of researchers from Yale University’s School of ... to provide electronic questionnaire data collection through use of ... in May, aims to evaluate the impact of a ... and participation in urban agriculture to impact their consumption ...
(Date:10/22/2014)... 22, 2014 Grace Century, a private ... projects, announces the addition of Dr. Yousef “Josh” ... advisory team. Dr. Siddiqui will provide further healthcare expertise ... graduate of University College Medical School in ... medicine in 2001. With further certification as a General ...
(Date:10/22/2014)... According to new market research report "Cloud ... Deployment & Support), by Service Model (SaaS, PaaS, ... (Hybrid & Community)) - Global Forecast to 2019", ... Professional Services Market into various sub-segments with an ... identifies the drivers and restraints for this market ...
(Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3
... (NASDAQ: ANPI , TSX: ANP), a global ... the first New Zealand patient,was treated with Cook ... 2007. A second patient was treated in February,2008. ... stent for peripheral,arterial disease (PAD) and was recently ...
... Krimpets for eight-weeks; 10% of all sales ... to be ... makers of the Tastykake snack line, today announced the re-issue,of Alex,s ... one of the nation,s leading organizations in the,fight against childhood cancer. ...
... SOUTH SAN FRANCISCO, Calif., and SINGAPORE, April 4, ... company focused on the,discovery and development of monoclonal ... Institute (BTI), today announced a,collaboration to advance the ... the terms of the agreement, Raven will license ...
Cached Biology Technology:Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4Tasty Baking Company Continues Partnership With Alex's Lemonade Stand Foundation To Fight Childhood Cancer 2Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies 2
muscle actin (HUC1-1)...
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
... Anti-NY-ESO-1, clone E978 ... NM_001327 Immunogen : ... Formulation: mouse ascites with ... Assurance: routinely evaluated by ...
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
Biology Products: